No association found between thiazolidinediones and bladder cancer
the ONA take:
According to a new study published in the journal Diabetologia, there is no link between either pioglitazone or rosiglitazone and bladder cancer.
For the study, the researchers collected prescription, cancer, and mortality data from 1.01 million people with type 2 diabetes from six populations in Europe and North America. Of those, 3,248 developed bladder cancer and only 117 of those were in patients who had taken pioglitazone.
Results showed that there was no link between cumulative exposure to the thiazolidinediones and bladder cancer in men or women after adjustment for other factors. In addition, longer exposure to pioglitazone did no increase the risk for developing bladder cancer.
According to the American Cancer Society, there will be an estimated nearly 75,000 new cases of bladder cancer and about 15,600 deaths from the disease. Men are about 3 to 4 times more likely to develop bladder cancer than women, but that risk is about 1 in 26 men.
Previous studies have shown that drugs from this class of antidiabetic drugs increases the risk of bladder cancer, but this study demonstrates otherwise. The authors suggest that studies with a longer duration of follow-up of patients exposed to pioglitazone or rosiglitazone be conducted to end the controversy.
There is no link between either pioglitazone or rosiglitazone and bladder cancer.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|